Patent number: 11802111
Abstract: Compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to depression, major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, and bipolar disorder), cancers and eye conditions: wherein R1, , R3, and L are as defined herein.
Type:
Grant
Filed:
September 21, 2021
Date of Patent:
October 31, 2023
Assignee:
Janssen Pharmaceutica NV
Inventors:
Jesus Alcazar, Michael K. Ameriks, Cynthia B. Berry, Pablo Garcia-Reynaga, Brian Ngo Laforteza, Andrew V. Samant